Ascendis Pharma A/S Company Profile (NASDAQ:ASND)

Analyst Ratings

Consensus Ratings for Ascendis Pharma A/S (NASDAQ:ASND) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.00 (84.47% upside)

Analysts' Ratings History for Ascendis Pharma A/S (NASDAQ:ASND)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016Leerink SwannReiterated RatingOutperform$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015Bank of America Corp.Initiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015Wells Fargo & Co.Initiated CoverageOutperform$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Ascendis Pharma A/S (NASDAQ:ASND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/22/2016        
5/20/2016Q1($0.55)($0.92)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.57)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/24/2015Q2($0.48)($0.73)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/18/2015Q115($0.37)$0.07$2.24 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ascendis Pharma A/S (NASDAQ:ASND)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.55)($0.55)($0.55)
Q2 20161($0.77)($0.77)($0.77)
Q3 20161($0.87)($0.87)($0.87)
Q4 20161($0.89)($0.89)($0.89)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ascendis Pharma A/S (NASDAQ:ASND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ascendis Pharma A/S (NASDAQ:ASND)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Ascendis Pharma A/S (NASDAQ:ASND)
DateHeadline
07/13/16 10:44 AMMarket Report, "Prostaglandin E2 Receptor EP2 Subtype - Pipeline Review, H1 2016", Published
07/05/16 07:23 AMAscendis Pharma (ASND): OrbiMed Advisors Adds More Shares
06/26/16 12:59 PMOrbiMed Advisors Buys Some More Ascendis Pharma (ASND) Shares -
05/26/16 10:15 AMAscendis Pharma A/S :ASND-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 -
05/19/16 03:52 PMAscendis Pharma A/S Reports First Quarter 2016 Financial Results - [at noodls] - COPENHAGEN, May 19, 2016 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical ...
02/25/16 08:04 AM9:04 am Ascendis Pharma appointed Jonathan Leff, M.D. as Chief Medical Officer -
02/25/16 08:00 AMAscendis Pharma A/S Appoints Jonathan A. Leff, M.D. as Chief Medical Officer - [PR Newswire] - COPENHAGEN, Denmark, Feb. 25, 2016 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet ...
02/03/16 04:00 PMAscendis Pharma A/S to Present at the Leerink Partners Global Healthcare Conference - [PR Newswire] - COPENHAGEN, Denmark, Feb. 3, 2016 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet ...
01/14/16 10:25 AMAscendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency - [at noodls] - COPENHAGEN, Denmark, July 30, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, ...
01/14/16 10:25 AMAscendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time - [at noodls] - COPENHAGEN, Denmark, July 29, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet ...
01/14/16 10:25 AMAscendis Pharma A/S Reports Second Quarter 2015 Financial Results - [at noodls] - Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results
01/14/16 10:25 AMJacob Gottlieb Adds To Position In Ascendis Pharma A/S (ASND); Armistice Capital Increases Stake In Demand Media Inc (DMD) -
01/14/16 10:25 AMAscendis Pharma A/S to Present at Three Upcoming Investor Conferences - [at noodls] - COPENHAGEN, Denmark, Sept. 3, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet ...
01/14/16 10:25 AMAscendis Pharma A/S Earnings Q2, 2015 -
01/14/16 10:25 AMAscendis Pharma A/S Reports Third Quarter 2015 Financial Results - [at noodls] - COPENHAGEN, Denmark, Nov. 12, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet ...
01/14/16 10:25 AMTwo Healthcare-Focused Funds Buy More Shares Of 2 Promising Companies, While Activist Cashes Out Of IT Company -
01/14/16 10:25 AMHow Do Hedge Funds Feel About AK Steel Holding Corporation (AKS)? -
01/14/16 10:25 AMAscendis Pharma A/S Earnings Analysis: Q3, 2015 By the Numbers -
12/08/15 12:08 PMASCENDIS PHARMA A/S Financials -
11/11/15 03:05 PMAscendis Pharma A/S to Present at the Stifel 2015 Healthcare Conference - [PR Newswire] - COPENHAGEN, Denmark, Nov. 11, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet ...
08/26/15 02:54 AMAusnutria Dairy Corporation Ltd 2015 Interim Gross Profit and Gross Profit Margin Increased by Approximately 7.3% and 3.0% Points Respectively - [PR Newswire] - HONG KONG, Aug. 26, 2015 /PRNewswire/ -- Business Highlights (As of 30 June 2015) Revenue of the own brands sector amounted to approximately RMB531.6 million, surging approximately 29.6% year-on-year, ...
08/25/15 08:20 AMWill OmniVision's (OVTI) Earnings Surprise Estimates in Q1? -

Social

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company's subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma and Endocrinology Division A/S (Denmark).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ASND
  • CUSIP:
Key Metrics:
  • Previous Close: $13.01
  • 50 Day Moving Average: $13.20
  • 200 Day Moving Average: $16.10
  • P/E Ratio: N/A
  • P/E Growth: -0.15
  • Market Cap: $326.92M
  • Beta: 0.09
  • Current Year EPS Consensus Estimate: $-3.54 EPS
  • Next Year EPS Consensus Estimate: $-2.08 EPS
Additional Links:
Ascendis Pharma A/S (NASDAQ:ASND) Chart for Thursday, July, 28, 2016